Victory Capital Management Inc. Has $479.38 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Victory Capital Management Inc. lowered its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 5.5% in the third quarter, Holdings Channel.com reports. The fund owned 2,934,485 shares of the company’s stock after selling 170,607 shares during the period. Johnson & Johnson makes up 0.6% of Victory Capital Management Inc.’s investment portfolio, making the stock its 10th largest holding. Victory Capital Management Inc.’s holdings in Johnson & Johnson were worth $479,377,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. RKL Wealth Management LLC lifted its position in shares of Johnson & Johnson by 2.1% in the 2nd quarter. RKL Wealth Management LLC now owns 48,233 shares of the company’s stock worth $8,562,000 after acquiring an additional 1,010 shares during the period. Geller Advisors LLC raised its holdings in shares of Johnson & Johnson by 7.5% in the 2nd quarter. Geller Advisors LLC now owns 9,260 shares of the company’s stock worth $1,644,000 after buying an additional 648 shares in the last quarter. Simon Quick Advisors LLC raised its holdings in shares of Johnson & Johnson by 296.9% in the 2nd quarter. Simon Quick Advisors LLC now owns 8,739 shares of the company’s stock worth $1,495,000 after buying an additional 6,537 shares in the last quarter. Lokken Investment Group LLC raised its holdings in shares of Johnson & Johnson by 1.6% in the 2nd quarter. Lokken Investment Group LLC now owns 12,968 shares of the company’s stock worth $2,302,000 after buying an additional 201 shares in the last quarter. Finally, Keebeck Alpha LP raised its holdings in shares of Johnson & Johnson by 13.4% in the 2nd quarter. Keebeck Alpha LP now owns 4,442 shares of the company’s stock worth $788,000 after buying an additional 525 shares in the last quarter. Institutional investors own 67.94% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of Johnson & Johnson stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the transaction, the chief financial officer now directly owns 35,812 shares in the company, valued at $6,431,835.20. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Johnson & Johnson news, EVP Ashley Mcevoy sold 73,323 shares of Johnson & Johnson stock in a transaction dated Wednesday, November 30th. The stock was sold at an average price of $175.47, for a total value of $12,865,986.81. Following the sale, the executive vice president now owns 41,813 shares of the company’s stock, valued at approximately $7,336,927.11. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Joseph J. Wolk sold 14,781 shares of Johnson & Johnson stock in a transaction dated Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total value of $2,654,667.60. Following the completion of the sale, the chief financial officer now directly owns 35,812 shares in the company, valued at approximately $6,431,835.20. The disclosure for this sale can be found here. Insiders have sold 233,611 shares of company stock worth $40,960,735 in the last three months. Insiders own 0.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on JNJ shares. Bank of America dropped their target price on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a report on Friday, October 14th. Raymond James dropped their price target on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a report on Wednesday, October 19th. SVB Leerink dropped their price target on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a report on Friday, January 20th. Citigroup raised their price target on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a report on Monday, December 12th. Finally, Atlantic Securities dropped their price target on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a report on Wednesday, October 19th. Seven equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average price target of $181.75.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $168.31 on Wednesday. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $440.04 billion, a P/E ratio of 23.44, a P/E/G ratio of 3.21 and a beta of 0.56. The stock’s fifty day simple moving average is $175.98 and its 200-day simple moving average is $171.06.

Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.23 by $0.12. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The business had revenue of $23.71 billion for the quarter, compared to analyst estimates of $23.90 billion. During the same period last year, the company earned $2.13 EPS. The firm’s revenue was down 4.4% on a year-over-year basis. Equities research analysts expect that Johnson & Johnson will post 10.04 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be given a $1.13 dividend. The ex-dividend date of this dividend is Friday, February 17th. This represents a $4.52 annualized dividend and a dividend yield of 2.69%. Johnson & Johnson’s dividend payout ratio is currently 62.95%.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.